TY - JOUR
T1 - Altered calcium handling is an early sign of streptozotocin-induced diabetic cardiomyopathy
AU - Ligeti, László
AU - Szenczi, Orsolya
AU - Prestia, Christina M.
AU - Szabó, Csaba
AU - Horváth, Katalin
AU - Marcsek, Zoltán L.
AU - Van Stiphout, Ruud G.P.M.
AU - Van Riel, Natal A.W.
AU - Den Buijs, Jorn Op
AU - Van Der Vusse, Ger J.
AU - Ivanics, Tamás
PY - 2006/6
Y1 - 2006/6
N2 - The main objective of the present study was to determine alterations of calcium handling in the diabetic rat heart during the transition from adaptive to maladaptive phase of cardiomyopathy. By inhibiting the nuclear enzyme poly(ADP-ribose) polymerase (PARP), we also investigated the possible role of this enzyme in the sequence of pathological events. Six weeks after induction of type I diabetes by injection of streptozotocin in rats, the hearts were perfused according to Langendorff. Intracellular-free calcium (Ca 2+i) levels were measured by surface fluorometry using Indo-1 AM. Cyclic changes in Ca2+i concentrations and hemodynamic parameters were measured simultaneously. The hearts were challenged by infusion of isoproterenol. Six weeks of diabetes resulted in reduced inotropy and lusitropy. The diabetic hearts (DM) expressed a significantly elevated end-diastolic Ca2+i level (control, 111±20 vs DM, 221±35 nM). The maximal transport capacity of SERCA2a and conductance of RyR2 were reduced. These changes were not accompanied by major alterations in the tissue content of SERCA2a, RyR2, phospholamban and Na+/Ca 2+ exchanger. In response to β-adrenergic activation, SERCA2a transport capacity and RyR2 conductance were stunted in the DM hearts. Inhibition of PARP induced minor changes in the mechanical function and calcium handling of the DM hearts. In conclusion, the observed changes in contractility and in Ca2+i handling are most likely attributable to functional disturbances of SERCA2a and RyR2 in this transitional phase of diabetes. At this stage of diabetes, PARP does not appear to play a significant pathogenetic role in the alterations in contractile function and calcium handling.
AB - The main objective of the present study was to determine alterations of calcium handling in the diabetic rat heart during the transition from adaptive to maladaptive phase of cardiomyopathy. By inhibiting the nuclear enzyme poly(ADP-ribose) polymerase (PARP), we also investigated the possible role of this enzyme in the sequence of pathological events. Six weeks after induction of type I diabetes by injection of streptozotocin in rats, the hearts were perfused according to Langendorff. Intracellular-free calcium (Ca 2+i) levels were measured by surface fluorometry using Indo-1 AM. Cyclic changes in Ca2+i concentrations and hemodynamic parameters were measured simultaneously. The hearts were challenged by infusion of isoproterenol. Six weeks of diabetes resulted in reduced inotropy and lusitropy. The diabetic hearts (DM) expressed a significantly elevated end-diastolic Ca2+i level (control, 111±20 vs DM, 221±35 nM). The maximal transport capacity of SERCA2a and conductance of RyR2 were reduced. These changes were not accompanied by major alterations in the tissue content of SERCA2a, RyR2, phospholamban and Na+/Ca 2+ exchanger. In response to β-adrenergic activation, SERCA2a transport capacity and RyR2 conductance were stunted in the DM hearts. Inhibition of PARP induced minor changes in the mechanical function and calcium handling of the DM hearts. In conclusion, the observed changes in contractility and in Ca2+i handling are most likely attributable to functional disturbances of SERCA2a and RyR2 in this transitional phase of diabetes. At this stage of diabetes, PARP does not appear to play a significant pathogenetic role in the alterations in contractile function and calcium handling.
KW - Cardiac function
KW - Diabetes
KW - Intracellular calcium handling
KW - Poly(ADP-ribose) polymerase
KW - RyR2
KW - SERCA2A
UR - http://www.scopus.com/inward/record.url?scp=33745685229&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33745685229&partnerID=8YFLogxK
U2 - 10.3892/ijmm.17.6.1035
DO - 10.3892/ijmm.17.6.1035
M3 - Article
C2 - 16685413
AN - SCOPUS:33745685229
SN - 1107-3756
VL - 17
SP - 1035
EP - 1043
JO - International journal of molecular medicine
JF - International journal of molecular medicine
IS - 6
ER -